4//SEC Filing
Chao Jennifer M 4
Accession 0000899243-20-032458
CIK 0000875622other
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 9:48 AM ET
Size
15.1 KB
Accession
0000899243-20-032458
Insider Transaction Report
Form 4
Chao Jennifer M
Director
Transactions
- Disposition to Issuer
Common Stock, $0.001 par value
2020-12-02−1,920→ 1,726 total - Disposition to Issuer
Stock Option (Right to Buy)
2020-12-02$46.68/sh−15,000$700,200→ 5,000 totalExercise: $41.82Exp: 2028-03-15→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-12-02$32.88/sh−5,000$164,400→ 0 totalExercise: $55.62Exp: 2030-03-13→ Common Stock (5,000 underlying) - Disposition to Issuer
Common Stock, $0.001 par value
2020-12-02−1,726→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2020-12-02$50.86/sh−1,687$85,801→ 20,000 totalExercise: $37.64Exp: 2025-04-22→ Common Stock (1,687 underlying)
Footnotes (5)
- [F1]Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 1,920 shares of common stock were exchanged for a cash payment of $169,920.00, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person.
- [F2]Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).
- [F3]Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (April 22, 2015), were canceled in exchange for a cash payment of $85,800.82, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
- [F4]Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (March 15, 2018), were canceled in exchange for a cash payment of $700,200.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
- [F5]Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which would have vested in full on the one-year anniversary of the grant date (March 13, 2020), were canceled in exchange for a cash payment of $164,400.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
Documents
Issuer
BIOSPECIFICS TECHNOLOGIES CORP
CIK 0000875622
Entity typeother
Related Parties
1- filerCIK 0001639625
Filing Metadata
- Form type
- 4
- Filed
- Dec 1, 7:00 PM ET
- Accepted
- Dec 2, 9:48 AM ET
- Size
- 15.1 KB